众生药业(002317.SZ)：众生睿创一类创新药RAY1225注射液两项降糖III期临床试验完成首例参与者入组

Core Viewpoint - The company, Zhongsheng Pharmaceutical, has announced the successful initiation of two Phase III clinical trials for its innovative peptide drug RAY1225 injection, targeting type 2 diabetes patients with inadequate blood sugar control [1] Group 1: Clinical Trials - The first trial (SHINING-2) is a multicenter, randomized, double-blind, placebo-controlled study focusing on type 2 diabetes patients with poor blood sugar control after dietary and exercise interventions [1] - The second trial (SHINING-3) is a multicenter, randomized, open-label study comparing RAY1225 with semaglutide injection in type 2 diabetes patients inadequately controlled on oral hypoglycemic agents [1] - The first participants have been enrolled and dosed in both clinical trials [1] Group 2: Drug Characteristics - RAY1225 injection is an innovative structural peptide drug developed by the company's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., with global independent intellectual property rights [1] - The drug exhibits dual agonistic activity on GLP-1 and GIP receptors, showing potential for long-acting administration with biweekly injections due to its excellent pharmacokinetic properties [1] - A third Phase III clinical trial (REBUILDING-2) assessing the safety and efficacy of RAY1225 in obese/overweight participants has completed participant enrollment [1]